Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TM...
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: GlobeNewswire
PHILADELPHIA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) as securities fraud class action complaint allegations have survived a motion to dismiss. If you purchased Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. WHY? Key allegations of a recently filed securities fraud class action complaint filed against Amylyx Pharmaceuticals, Inc., (NASDAQ: AMLX) and certain of its officers, have now survived Defendants’ motion to dismiss that complaint. The underly
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/SBusiness Wire
- Amylyx Pharmaceuticals (NASDAQ:AMLX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AMLX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
AMLX
Earnings
- 11/6/25 - Beat
AMLX
Sec Filings
- 1/16/26 - Form 144
- 1/16/26 - Form 144
- 1/15/26 - Form 144
- AMLX's page on the SEC website